{
  "denotations": [
    {
      "id": "T1",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 71,
        "end": 75
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 104,
        "end": 113
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 154,
        "end": 158
      }
    },
    {
      "id": "T5",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 223,
        "end": 227
      }
    },
    {
      "id": "T6",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 28,
        "end": 68
      }
    },
    {
      "id": "T7",
      "obj": "Chemical",
      "span": {
        "begin": 0,
        "end": 11
      }
    },
    {
      "id": "T8",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 119,
        "end": 151
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 119,
        "end": 184
      }
    },
    {
      "id": "T11",
      "obj": "Disease",
      "span": {
        "begin": 223,
        "end": 258
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 28,
        "end": 97
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "21135276_3",
  "text": "Trastuzumab , the humanized human epidermal growth factor receptor 2 ( HER2 ) monoclonal antibody , and lapatinib , an epidermal growth factor receptor / HER2 tyrosine kinase inhibitor , are both established treatments for HER2 -overexpressing breast cancers ."
}
